Kubota Pharmaceutical Holdings Co., Ltd. (TYO:4596) Files An 8-K Results of Operations and Financial Condition

On May 10, 2017>(Japan Standard Time), Kubota Pharmaceutical
Holdings Co., Ltd. (the “Company”) filed with the Tokyo Stock
Exchange a Japanese report referred to as Kessan Tanshin, (the
“Tanshin”) which contained the Company’s unaudited financial
results for the three months ended March 31, 2017. A copy of the
English translation of the Tanshin is attached hereto as Exhibit
99.1.

The information furnished in this Form 8-K, including the exhibit
hereto, shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act), or
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such a filing.

The statements contained in the Tanshin and this Form 8-K regarding
projected financial results for the year ending December 31, 2017
are forward-looking statements made to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. The
Company has based these forward-looking statements largely on its
expectations and projections about future events and financial
trends affecting the financial condition and/or operating results
of its business. These statements involve risks and uncertainties
that could cause the Companys actual results to differ materially,
including, but not limited to the risk that our product candidates
will not demonstrate the expected benefits and will not achieve
regulatory approval or be successfully commercialized, the risk of
delays in our expected clinical trials, the risk that new
developments in the intensely competitive ophthalmic pharmaceutical
and device markets require changes in our clinical trial plans or
limit the potential benefits of our product candidates, the risk
that our pre-clinical development efforts may not yield additional
product candidates, the impact of expanded product development and
clinical activities on operating expenses, our dependence on and
our ability to retain and motivate our key management and
scientific staff, and other risks and uncertainties inherent in the
process of discovering and developing therapeutics and devices that
demonstrate safety and efficacy. For a detailed discussion of these
and other risk factors, please refer to the Companys filings with
the Securities and Exchange Commission, which are available on the
Companys investor relations Web site
(http://http://www.kubotaholdings.co.jp/en/ir/index.html) and on
the SECs Web site (http://www.sec.gov).